Sysmex Corporation (TYO:6869)

Market Cap	975.54B -36.6%
Revenue (ttm)	500.01B -1.7%
Net Income	35.46B -33.9%
EPS	56.89 -33.9%
Shares Out	605.74M
PE Ratio	28.31
Forward PE	24.49
Dividend	40.00 (2.51%)
Ex-Dividend Date	Sep 29, 2026

Volume	2,640,500
Open	1,591.50
Previous Close	1,610.50
Day's Range	1,584.50 - 1,629.50
52-Week Range	1,246.00 - 2,529.50
Beta	0.69
Analysts	Buy
Price Target	1,760.00 (+8.21%)
Earnings Date	Aug 7, 2026

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1968
• Employees: 10,861
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6869

Financial Performance

In fiscal year 2026, Sysmex's revenue was 500.01 billion, a decrease of -1.70% compared to the previous year's 508.64 billion. Earnings were 35.46 billion, a decrease of -33.93%.

Analyst Summary

According to 14 analysts, the average rating for 6869 stock is "Buy." The 12-month stock price target is ¥1,760, which is an increase of 8.21% from the latest price.

Price Target

¥1,760

(8.21% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 5, 2026

Data Sources Report a data error